Prestige Biopharma participates in US gov’t Cancer Moonshot

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will participate in the US government's cancer eradication project "Cancer Moonshot."

According to company sources, CancerX, a public-private collaboration established to drive the Cancer Moonshot, has selected Prestige Biopharma as a member, recognizing that its pancreatic cancer treatment strategy aligns with the project's goals.

The company explained that since CancerX publicly disclosed around 90 founding member companies last month, it has been actively enlisting additional companies in the field of cancer therapeutics.

Prestige Biopharma possesses drug candidates such as PBP1510 (ulenistamab), which neutralizes the gene PAUF (pancreatic adenocarcinoma up-regulated factor) excessively expressed in pancreatic cancer patients. Through this participation, the company plans to conduct various research related to pancreatic cancer diagnosis, treatment, and prevention utilizing PAUF concentrations.

The Cancer Moonshot was initially mentioned during the tenure of former US President Barack Obama, with the aim of national support for cancer prevention, early detection and the development of therapies. It is currently being pursued by President Joe Biden.

Write to In-hyuk Park at hyuk@hankyung.com